Active Surveillance in 2021 Part 2: Imaging and Biomarkers

Matthew Cooperberg, MD, MPH on Biomarkers in Prostate Cancer Active SurveillanceПодробнее

Active Surveillance 2021 (Part 3) - Patient Selection, Monitoring, and Innocuous InterventionsПодробнее

Active Surveillance 2021 - From Bench to BedsideПодробнее

What Role Do Markers Play in Establishing Active Surveillance or Definitive Care?Подробнее

Active Surveillance Results and Implications of Prospective StudiesПодробнее

Biomarkers’ Integration with Clinical Parameters, Imaging, and Prognostic InstrumentsПодробнее

Active Surveillance 2022: Who Qualifies, Who Does Not and How Should it be MonitoredПодробнее

Active Surveillance Criteria and Follow-up ProtocolПодробнее

Biomarkers to guide active surveillanceПодробнее

Active Surveillance – When Can You Continue Watching and When Do You Intervene?Подробнее

Biomarkers and ImagingПодробнее

Identifying optimal candidates for active surveillance in prostate cancerПодробнее

Screening and Prevention of Prostate Cancer 2021: Incorporating MRI for Early DetectionПодробнее

Active Surveillance Who is the Right Patient and What is the Right ProtocolПодробнее

Screening and Prevention of Prostate Cancer 2021 - Who Needs a Biopsy?Подробнее

Lecture 1. Introducing imaging biomarkers for prostate cancer careПодробнее

Dr. Klotz - What's New in Active Surveillance for Prostate Cancer in 2021Подробнее

Active Surveillance in Favorable Intermediate-Risk Prostate CancerПодробнее

MRI for Active Survelliance 2021 UpdateПодробнее